Basilea Pharmaceutica Ltd. provided preliminary revenue guidance for the financial year 2018. For the year, the company expects total revenue to increase by 31% over 2017 to approximately CHF 133 million compared to CHF 101.5 million a year ago, with contributions of approximately CHF 82 million compared to CHF 52.5 million, increased by 56% from Basilea's two marketed products, the antifungal Cresemba(®) (isavuconazole) and the antibiotic Zevtera(®) (ceftobiprole) a year ago. Basilea had guided for total revenue of CHF 120 million - 130 million and contributions from Cresemba and Zevtera of CHF 75 million - 85 million for the financial year 2018.